Ignite Creation Date:
2025-12-24 @ 5:05 PM
Ignite Modification Date:
2026-05-29 @ 6:44 AM
Study NCT ID:
NCT05745350
Status:
RECRUITING
Last Update Posted:
2025-02-11
First Post:
2023-02-05
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC
Sponsor:
Xiaorong Dong
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
KeyPemls-005
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None